Effect of lopinavir and efavirenz on pharmacokinetics and pharmacodynamics of glibenclamide in diabetic rats

Prashanth Vennapanja, Ajmera Ramarao

Abstract


Objective: The aim of the study is whether the impact of Efavirenz and Lopinavir will increase the plasma level of Glibenclamide or not. Efavirenz and Lopinavir is an antiretroviral drug to treat HIV AIDS and inhibits cytochrome P450-3A4. Multiple CYP isoforms are involved in the metabolism of Glibenclamide like CYP2C8 and CYP3A4. Hence there is more possibility of Efavirenz and Lopinavir to inhibit the metabolism of Glibenclamide by inhibiting CYP 3A4.

Methods: Efavirenz and Lopinavir (10 mg/kg,p.o.) alone and along with Glibenclamide (10 mg/kg, p.o.) was given to normal and diabetic rats. PK/PD parameters were studied. In the rats co-treated with Efavirenz and Lopinavir and Glibenclamide.

Results: The pharmacokinetic parameters like clearance of Glibenclamide was reduced, peak plasma concentration, area under the plasma concentration time curve and elimination half-life were significantly increased when compared to pioglitazone treated rats.

Conclusions: This study revealed that lopinavir and efavirenz affected the disposition of Glibenclamide in rats probably by the inhibition of CYP3A4, leading to increasing Glibenclamide concentrations that could increase the efficacy of Glibenclamide or it may causes severe hypoglycemia. Therefore, its warrants to use relatively less dose of Glibenclamide than the normal dose.

Keywords


Lopinavir, Efavirenz, Glibenclamide, Diabetic rats, Drug-drug interactions

Full Text:

PDF HTML XML

References


Sproule BA, Naranjo CA, Brenmer KE, Hassan PC. Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence. Clin Pharmacokinet. 1997;33:454−71.

Tahseen M, Munwar K, Rama Narsimha Reddy A. influence of fluoxetine on pharmacokinetics and pharmacodynamics of glibenclamide in diabetic rats. Asian J Pharm Clin Res. 2014;7(2):76-9.

Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: Interactions between antiepileptic drugs and other drugs. Lancet Neurol. 2003;2:473−81.

Sujatha S, Ciddi V. Pharmacokinetic and Pharmacodynamic Interaction of Boswellic Acids and Andrographolide with Glyburide in Diabetic Rats: Including Its PK/PD Modeling. Phytother Res. 2016;30:496–502.

Prasad N, Keerthana C. Effects of ritonavir on the pharmacokinetics and pharmaco-dynamics. J Pharm Res. 2012;5(2):958-62.

Gumieniczek A. Modification of oxidative stress by pioglitazone in the heart of alloxan-induced diabetic rabbits. J Biomed Sci. 2005;12(3):531-7.

Sultanpur C, Satyanarayana S, Reddy N, Kumar K, Kumar S. Drug-drug Interaction between Pravastatin and Gemfibrozil (Antihyperlipidemic) with Gliclazide (Antidiabetic) in Rats. J Young Pharm. 2010;2(2):152-5.

Heikkila RE. The prevention of alloxan induced diabetes in mice by dimethyl sulfoxide. Eur J Pharmacol. 1977;44(2):191-3.

Prasad N, Jyostna G. Influence of Atorvastatin on the Pharmacokinetics and Pharmacodynamics of Glyburide in normal and diabetic rats. Eur J Pharm Sci. 2011;42:285-9.

Balani SK, Kauffman LR, Deluna FA, Lin JH. Department of Drug Metabolism, Merck Research Laboratories, West Point, Pennsylvania (Received April 16, 1998;accepted August 7, 1998) Vol. 27, No. 1.

Fuhr U. Induction of drug metabolising enzymes: pharmacokinetic and toxicological consequences in humans. Clin Pharmacokinet. 2000;38:493-504.

Waxman DJ. P450 gene induction by structurally diverse xenochemicals:central role of nuclear receptors CAR, PXR, and PPAR. Arch Biochem Biophys. 1999;369:11-23.

Lin JH, Lu AYH. Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet. 1998;35:361-90.

David BT, Remington. The science and practice of pharmacy. 21st ed. Philadelphia: Lippincott Williams and Wilkins; 2005: 1889.

Pearson JG, Antal EJ, Raehl CL, Gorsch HK, Craig WA, Albert KS, Welling PG. Pharmacokinetic disposition of 14C-glyburide in patients with varying renal function. Clin Pharmacol Ther. 1986;39:318-24.

Srinivas M, Nayanabhirama U. Formulation development in vitro and in vivo evaluation of membrane controlled transdermal systems of glibenclamide. J Pharm Pharmacol Sci. 2005;8:26–38.

Peart GF, Boutagy J, Shenfield GM. The metabolism of glyburide in subjects of known debrisoquin phenotype. Clin Pharmacol Ther. 1989;45:277-84.

Rydberg T, Jönsson A, Karlsson MO, Melander A. Concentration-effect relations of glibenclamide and its active metabolites in man:modelling of pharmacokinetics and pharmacodynamics. Br J Clin Pharmacol. 1997;43:373-81.

Rydberg T, Jönsson A, Melander A. Comparison of the kinetics of glyburide and its active metabolites in humans. J Clin Pharm Ther. 1995;20:283-95.

Rydberg T, Jönsson A, Røder M, Melander A. Hypoglycemic activity of glyburide (glibenclamide) metabolites in humans. Diabetes Care. 1994;17:1026-30.




DOI: http://dx.doi.org/10.26510/2394-0859.pbe.2017.38

Refbacks

  • There are currently no refbacks.




Copyright (c) 2017 Pharmaceutical and Biological Evaluations

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.



Creative Commons License

 

© Copyright 2017 - Pharmaceutical and Biological Evaluations